Can-Fite BioPharma (CANF) News Today $1.18 -0.05 (-3.66%) As of 03:07 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite's Namodenoson, Leading U.S. Medical Centers Seek Authorization for their PatientsApril 17 at 8:55 AM | globenewswire.comCan-Fite Reports 2024 Financial Results and Clinical UpdateApril 14 at 10:54 PM | markets.businessinsider.comCan-Fite to Generate $685M in Projected Future Revenues from its PartnershipsApril 14 at 10:54 PM | finance.yahoo.comCan-Fite BioPharma Secures $3 Million in Direct OfferingApril 14 at 5:16 PM | tipranks.comCan-Fite Announces $3.0 Million Registered Direct Offering of American Depositary SharesApril 14 at 2:28 PM | globenewswire.comCan-Fite BioPharma (NYSE:CANF) Coverage Initiated by Analysts at StockNews.comApril 8, 2025 | americanbankingnews.comCan-Fite BioPharma Initiates Pivotal Phase 3 Study for Oral Drug Piclidenoson in Psoriasis TreatmentMarch 26, 2025 | nasdaq.comCan-Fite Initiates Pivotal Phase 3 Psoriasis Study of its Oral Drug Piclidenoson with FDA & EMA-Approved ProtocolMarch 24, 2025 | markets.businessinsider.comCan-Fite BioPharma Projects $325 Million in Revenue from Piclidenoson Under Veterinary Partnership with VetbiolixMarch 22, 2025 | nasdaq.comCan-Fite BioPharma Initiates Phase II Clinical Study for Piclidenoson in Patients with Lowe SyndromeMarch 21, 2025 | nasdaq.comCan-Fite BioPharma to initiate Phase II study in Lowe SyndromeMarch 21, 2025 | markets.businessinsider.comCan-Fite BioPharma Advances Canine Osteoarthritis Treatment with Vetbiolix PartnershipMarch 20, 2025 | tipranks.comCan-Fite Partner Vetbiolix Accelerate Piclidenoson Development with Advanced Clinical Trial for Canine Osteoarthritis in a $3.8 Billion MarketMarch 20, 2025 | globenewswire.comCan-Fite BioPharma Ltd.: Can-Fite to Initiate Phase II Study in the Rare Genetic Disease Lowe Syndrome with PiclidenosonMarch 19, 2025 | finanznachrichten.deCan-Fite to Initiate Phase II Study in the Rare Genetic Disease Lowe Syndrome with PiclidenosonMarch 19, 2025 | globenewswire.comCan-Fite announces FDA approved compassionate use treatment of NamodenosonMarch 18, 2025 | msn.comCan-Fite: FDA Approved Compassionate Use Treatment with Namodenoson in a Pancreatic Cancer PatientMarch 18, 2025 | tmcnet.comFDA Approves Compassionate Use of Can-Fite’s Namodenoson for Pancreatic CancerMarch 18, 2025 | tipranks.comCan-Fite Innovative Publication: Namodenoson in Liver Cancer Treatment Alongside with Cardiac, Liver, and Neurological BenefitsMarch 3, 2025 | globenewswire.comDisappearance of Decompensated Liver Cirrhosis Episodes After Treatment with Can-Fite's NamodenosonFebruary 18, 2025 | finance.yahoo.comDisappearance of Decompensated Liver Cirrhosis Episodes After Treatment with Can-Fite's NamodenosonFebruary 18, 2025 | finance.yahoo.comCan-Fite reports disappearance of decompensated liver cirrhosis episodesFebruary 18, 2025 | markets.businessinsider.comCan-Fite’s Namodenoson Shows Promise in Treating Liver CirrhosisFebruary 18, 2025 | tipranks.comJoin Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on February 25February 10, 2025 | finance.yahoo.comJoin Can-Fite's Exclusive Live Investor Webinar and Q&A Session on February 25February 10, 2025 | globenewswire.comCan-Fite BioPharma to Present Namodenoson at Upcoming BIO CEO ConferenceFebruary 5, 2025 | tipranks.comCan-Fite BioPharma to Present the Namodenoson Anti-Obesity Effect at BIO CEO & Investor Conference 2025February 5, 2025 | globenewswire.comCan-Fite BioPharma secures US patent for NamodenosonJanuary 28, 2025 | msn.comCan-Fite BioPharma announces U.S. patent office granted patent to NamodenosonJanuary 28, 2025 | markets.businessinsider.comCan-Fite Wins Patent, Shares FlatJanuary 27, 2025 | baystreet.caUS Patent Office Granted Can-Fite Namodenoson Patent for Use as anti-Obesity DrugJanuary 27, 2025 | markets.businessinsider.comCan-Fite BioPharma Secures US Patent for Anti-Obesity Drug NamodenosonJanuary 27, 2025 | tipranks.comD. Boral says Can-Fite’s namodenoson may represent liver cancer ‘paradigm shift’January 1, 2025 | markets.businessinsider.comRecognition of the American Society of Clinical Oncology (ASCO) of the Liver Protective Effect of Can-Fite’s anti-Cancer Drug NamodenosonDecember 30, 2024 | markets.businessinsider.comRecognition of the American Society of Clinical Oncology (ASCO) of the Liver Protective Effect of Can-Fite's anti-Cancer Drug NamodenosonDecember 30, 2024 | globenewswire.com8 Years Survival with Complete Cure for a Patient with Advanced Liver Cancer Being Treated with Can-Fite’s Namodenoson DrugDecember 4, 2024 | finance.yahoo.com60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TVNovember 22, 2024 | finanznachrichten.deCan-Fite Biopharma Ltd. ADRNovember 20, 2024 | wsj.comCan-Fite BioPharma Advances in Pancreatic Cancer TrialNovember 13, 2024 | markets.businessinsider.comCan-Fite BioPharma Ltd.: Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical TrialNovember 11, 2024 | finanznachrichten.deCan-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical TrialNovember 11, 2024 | globenewswire.comCan-Fite BioPharma Secures Australian Patent for Obesity DrugNovember 4, 2024 | markets.businessinsider.comCan-Fite BioPharma announces an update related to IP status of NamodenosonNovember 4, 2024 | markets.businessinsider.comCan-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in AustraliaNovember 4, 2024 | globenewswire.comCan Fite Biofarma (AMEX:CANF) Stock Quotes, Forecast and News SummaryOctober 22, 2024 | benzinga.comSignificant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with PiclidenosonOctober 18, 2024 | globenewswire.comCan-Fite BioPharma Rises 17% After Pancreatic-Cancer Drug Gets Orphan DesignationOctober 9, 2024 | marketwatch.comFDA Grants Orphan Drug Designation to Can-Fite’s Namodenoson for Pancreatic CancerOctober 9, 2024 | markets.businessinsider.comFDA Grants Orphan Drug Designation to Can-Fite's Namodenoson for Pancreatic CancerOctober 9, 2024 | globenewswire.comJoin Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on October 29October 7, 2024 | finance.yahoo.com Remove Ads Get Can-Fite BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CANF and its competitors with MarketBeat's FREE daily newsletter. Email Address CANF Media Mentions By Week CANF Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CANF News Sentiment▼0.280.80▲Average Medical News Sentiment CANF News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CANF Articles This Week▼51▲CANF Articles Average Week Remove Ads Get Can-Fite BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CANF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Natural Alternatives International News Enlivex Therapeutics News ProMIS Neurosciences News RenovoRx News Q32 Bio News Grace Therapeutics News Lakeshore Biopharma News Rallybio News Annovis Bio News Cardio Diagnostics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:CANF) was last updated on 4/17/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredFeds Just Admitted It—They Can Take Your CashHere’s the cold truth: If your money is sitting idle in a bank account, it’s vulnerable. That’s why thousan...Priority Gold | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Can-Fite BioPharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Can-Fite BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CANF Stock Free CANF Stock Alerts